A series of potent, selective inhibitors of protein kinase C has been derived from the structural lead provided by the microbial broth products, staurosporine and K252a. Our inhibitors block PCK in intact cells (platelets and T cells), and prevent the proliferation of mononuclear cells in response to interleukin 2 (IL2).

The value of the FIC index as a predictor of synergy has been investigated using the antibacterial agents alafosfalin and cephalexin combined together with themselves in fully blind experiments. Under the conditions used, even weak interaction (FIC index 0.5-0.99) proved to be statistically highly significant. The use of such fully controlled blind studies would greatly enhance the credibility of many of the claims of synergy published in the literature. The representation of results as average isobolograms is only of value with combinations which show moderate to strong interaction.

No abstract

Phosphonopeptides based on aminomethylphosphonic acid as the C-terminal residue linked to L-amino acids possessed antibacterial activity in vitro and in vivo. Analogs in this series were generally less potent than corresponding compounds based on L-1-aminoethylphosphonic acid such as alafosfalin (L-alanyl-L-1-aminoethylphosphonic acid). Significant differences in antibacterial spectra were observed. The mechanism of action involved active transport of the peptide mimetics into the bacterial cells, followed by intracellular release of high concentrations of aminomethylphosphonic acid which inhibited bacterial cell wall biosynthesis. Aminomethylphosphonic acid behaved as a mimetic of both D-and L-alanine and inhibited D-Ala-D-Ala synthetase (EC 6.3.2.4.), alanine racemase (EC 5.1.1.1.), and UDP-N-acetylmuramyl-L-alanine synthetase (EC 6.3.2.8.). The minimal inhibitory concentration of L-norvalyl-aminomethylphosphonic acid was essentially unaffected by the presence of D-alanine, whereas the activity of the corresponding L-norvalyl derivative of L-1-aminoethylphosphonic acid was markedly decreased. Substantial differences in the inhibitory and lytic activity of the Lnorvalyl derivatives of aminomethylphosphonic and L-1-aminoethylphosphonic acids were also observed when these agents were combined with other inhibitors of bacterial cell wall biosynthesis.Previous papers have described results of investigations on the antibacterial properties of phosphonopeptides (1-7). Alafosfalin [L-alanyl-L-1-aminoethylphosphonic atid; L-Ala-L-Ala(P)] has been selected for clinical studies in humans. Other related compounds incorporating L-Ala(P) are of interest for particular applications in therapy.In these studies, phosphonopeptides with alternative aminoalkylphosphonic acid residues were investigated. Phosphonopeptides incorporating aminomethylphosphonic acid, Gly(P), were the only compounds with levels of antibacterial activity comparable with those of the L-

No abstract